BioWorld

March 9, 2006

View Archived Issues

In Huntington's, Are Inclusion Bodies Answer, Not Problem?

Read More

Neuromed's $25M To Fuel Calcium Channel Research

Read More

Alexza Prices IPO At $44M To Finance Clinical Work

Read More

Clinical Roundup

Read More

Other News To Note

Read More

FDA Committee Advocates Tysabri's Return To Market

GAITHERSBURG, Md. - Members of an FDA advisory committee voted unanimously in favor of bringing Tysabri (natalizumab) back to the multiple sclerosis market, but with restrictions. (BioWorld Today) Read More

Neurocrine Dropping APL-MS Work After Missed Endpoint

Read More